Clinical trial NCT00413777 - References

Polycystic Kidney, Autosomal Dominant — Tolvaptan Open-Label Pilot Efficacy, Tolerability and Safety Study in ADPKD

Citation(s)

•   Gattone VH 2nd, Wang X, Harris PC, Torres VE
  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003 Oct;9(10):1323-6. Epub 2003 Sep 21.
•   Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd
  Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004 Apr;10(4):363-4. Epub 2004 Feb 29.

A Phase 2, Multi-center, Open-label Study to Determine Long-term Safety, Tolerability and Efficacy of Split-dose Oral Regimens of Tolvaptan Tablets in a Range of 30 to 120 mg/d in Patients With Autosomal Dominant Polycystic Kidney Disease

Details for clinical trial NCT00413777